Prevail Therapeutics Inc (PRVL) |
|
|
|
Prevail Therapeutics Inc Growth Comparisons
Select each growth Category to receive further Information
Select the Comparisons :
|
|
Select the Ratio:
|
|
PRVL's Growth Comparisons in III. Quarter 2020
Prevail Therapeutics Inc reported top-line of $ 0 millions in the third quarter 2020, compare to $ 0 millions in the same quarter a year ago. Revenues in the Biotechnology & Pharmaceuticals industry grew by 29.34%, while the top-line in the Healthcare sector increased by 8.77%, and overall market declined by -2.03% from the third quarter 2019. Sequentially company's Revenue were unchanged from the second quarter results. . Looking into annual growth, sales grew by % on average in last five years, while S & P 500's including only Businesses with the third quarter 2020 earnings reports, average yearly sales growth is 10.54%.
Growth Rates of PRVL's Income in the third quarter 2020
PRVL's EPS Growth Rates
Prevail Therapeutics Inc reported bottom-line of $ -0.55 in the third quarter, compare to $ -0.62 in the same quarter a year ago. Biotechnology & Pharmaceuticals industry grew by 198.11%, while Healthcare sector increased by 16.95%, and overall market declined by -10.3%. Sequentially company's EPS were unchanged from the second quarter results. . Looking into annual growth, income per share grew by % on average in the last five years, while the S & P 500's including only the businesses with the third quarter 2020 financial results, average yearly income per share growth is 11.57%.
PRVL Cash Flow Growth Rates
|